Literature DB >> 17552042

A review of the sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised sapporo criteria add value?

Raja S Bobba1, Sindhu R Johnson, Aileen M Davis.   

Abstract

OBJECTIVE: The preliminary classification criteria for antiphospholipid syndrome (APS), or the Sapporo criteria, are widely used for the inclusion of patients with APS into clinical studies. Revised Sapporo criteria have been proposed as an improved criteria set. Whether these criteria sets fulfill the current standards of measurement science are unknown. The purpose of this study was (1) to evaluate the developmental methodology and measurement properties of the Sapporo and the revised Sapporo criteria for use in clinical trials; and (2) to evaluate if the revised Sapporo criteria provide added value over the Sapporo criteria.
METHODS: A computer search for articles describing use of the Sapporo and the revised Sapporo criteria was performed. Item generation, item reduction, sensibility, validity, and reliability of the criteria were evaluated.
RESULTS: The Sapporo criteria set has incremental face and content validity over its predecessors. However, through separation of anti-ss2-glycoprotein I antibodies as a sub-item, the specification of a wider time interval between serologic testing, the specification of a time interval between serology and clinical manifestations, and specification of definitions for clinical manifestations and laboratory titer thresholds, the revised Sapporo criteria set has incremental face and content validity over the Sapporo criteria. The complexity of the criteria, diagnostic tests, and immunologic tests limits their feasibility. The reliability of each criterion is unknown. The discriminative capacity of the Sapporo criteria is good, with sensitivity, specificity, and positive and negative predictive values of 0.71, 0.98, 0.95, and 0.88, respectively, compared to patients with systemic lupus erythematosus. The discriminative capacity of the revised Sapporo criteria is unknown.
CONCLUSION: The revised Sapporo criteria set has incremental face and content validity compared its predecessors. Reliability testing of each criterion is needed before these criteria can be confidently used in multicenter APS trials. Discriminatory testing of the revised Sapporo criteria is required.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17552042

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus.

Authors:  Sara G Murray; Jinoos Yazdany; Rachel Kaiser; Lindsey A Criswell; Laura Trupin; Edward H Yelin; Patricia P Katz; Laura J Julian
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-09       Impact factor: 4.794

2.  The first reported case of factor V Leiden mutation with agenesis of superior vena cava: A case report.

Authors:  Valter Romão De Souza; Victor Moreira Valença de Lemos; Daniell de Siqueira Araújo Lafayette; Roberto Souza de Lemos; Luciana de Barros Correia Fontes; Glaydes Maria Torres de Lima; Cláudia Wanderley de Barros Correia; Ana Lucia Coutinho Domingues; Amanda Queiroz da Mota Silveira Aroucha; Igor Macedo de Oliveira; Gabriel Pinheiro Santos; Ana Maria Vanderlei; Vladmyr Moreira Valença de Lemos; João Vitor Sostenes Peter; Juliana Oliveira Vieira; Aline Rayane Pereira Mariano; Turíbio Anacleto Gomes; Alice Marcelle de Souza Ferraz; José Henrique Sousa do Amaral; Esdras Marques Lins; Marcos André Cavalcanti Bezerra; Paulo Sérgio Ramos de Araújo; Adriana Ferraz de Vasconcelos; Maria da Conceição de Barros Correia; Manuela Freire Hazin Costa
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

Review 3.  Epidemiology of Antiphospholipid Syndrome in the General Population.

Authors:  Jesse Y Dabit; Maria O Valenzuela-Almada; Sebastian Vallejo-Ramos; Alí Duarte-García
Journal:  Curr Rheumatol Rep       Date:  2022-01-05       Impact factor: 4.592

4.  The effect of the BNT162b2 vaccine on antinuclear antibody and antiphospholipid antibody levels.

Authors:  Hussein A Noureldine; Julian Maamari; Mohamad Othman El Helou; Georges Chedid; Anna Farra; Roula Husni; Jacques E Mokhbat
Journal:  Immunol Res       Date:  2022-08-18       Impact factor: 4.505

5.  Clinical Application of Revised Laboratory Classification Criteria for Antiphospholipid Antibody Syndrome: Is the Follow-Up Interval of 12 Weeks Instead of 6 Weeks Significantly Useful?

Authors:  Sang Hyuk Park; Seongsoo Jang; Chan-Jeoung Park; Hyun-Sook Chi
Journal:  Biomed Res Int       Date:  2016-08-17       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.